Prediction of pathological stage in patients with clinical stage T1c prostate cancer: The new challenge

被引:23
作者
Veltri, RW
Miller, MC
Mangold, LA
O'Dowd, GJ
Epstein, JI
Partin, AW
机构
[1] Johns Hopkins Med Inst, Brady Urol Inst, Baltimore, MD 21205 USA
[2] Immunicon Corp, Huntingdon, PA USA
[3] UroCor Inc, Oklahoma City, OK USA
关键词
prostate; prostatic neoplasms; prostate-specific antigen; tumor markers; biological; neoplasm staging;
D O I
10.1016/S0022-5347(05)64839-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We developed an algorithm for predicting the likelihood of organ confined disease in patients with clinical stage T1c prostate cancer using biopsy pathology, computer assisted image analysis and serum prostate specific antigen (PSA). Materials and Methods: Of the 557 consecutive men enrolled in this study between October 1998 and January 2000 scheduled for radical prostatectomy at a single institution 386 (69%) presented with clinical stage T1c disease. Study exclusion criteria included neoadjuvant hormonal treatment with luteinizing hormone-releasing hormone, antiandrogen or 5alpha-reductase inhibitors. Preoperative serum, biopsy histology slides, clinical demographic information, prostatectomy pathology and prostate weight data were obtained. Biomarkers assessed included total PSA, complexed PSA, free PSA, the free-to-total PSA ratio, quantitative nuclear grade determined by image analysis, complexed PSA density, and biopsy Gleason grade and score. To determine patient specific quantitative nuclear grade values, images from approximately 125 cancer nuclei were captured per patient from the area of the biopsy section with the highest Gleason score. The variance in 60 nuclear size, shape and chromatin texture descriptors was calculated for each gallery of nuclei. Logistic regression was done to determine the most accurate combination of variables for predicting organ confined prostate cancer. Results: Complete results and data were available on 255 of the 386 men (66%) with an average age plus or minus standard deviation of 58.8 +/- 6 years who had stage T1c disease, including 49 (19%) with pathologically nonorgan confined disease. Logistic regression analysis revealed that quantitative nuclear grade, biopsy Gleason score, total PSA, the calculated free-to-total PSA ratio, complexed PSA and complexed PSA density were univariately significant for predicting organ confined disease (p < 0.05). On backward stepwise logistic regression only quantitative nuclear grade, complexed PSA density and Gleason score remained in a model yielding an area under the receiver operating characteristics curve of 82.4%. Conclusions: The quantitative nuclear grade biomarker was the strongest independent predictor of pathological stage in men with clinical stage T1c prostate cancer when combined with biopsy Gleason score and complexed PSA density data.
引用
收藏
页码:100 / 104
页数:5
相关论文
共 24 条
  • [1] An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level
    Badalament, RA
    Miller, MC
    Peller, PA
    Young, DC
    Bahn, DK
    Kochie, P
    ODowd, GJ
    Veltri, RW
    [J]. JOURNAL OF UROLOGY, 1996, 156 (04) : 1375 - 1380
  • [2] Cher ML, 1996, CANCER RES, V56, P3091
  • [3] Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy
    Ghavamian, R
    Blute, ML
    Bergstralh, EJ
    Slezak, J
    Zincke, H
    [J]. UROLOGY, 1999, 54 (01) : 105 - 110
  • [4] Cancer statistics, 2000
    Greenlee, RT
    Murray, T
    Bolden, S
    Wingo, PA
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2000, 50 (01) : 7 - 33
  • [5] Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy - The 15-year Johns Hopkins experience
    Han, M
    Partin, AW
    Pound, CR
    Epstein, JI
    Walsh, PC
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2001, 28 (03) : 555 - +
  • [6] Molecular and cellular biology of prostate cancer
    Lalani, EN
    Laniado, ME
    Abel, PD
    [J]. CANCER AND METASTASIS REVIEWS, 1997, 16 (1-2) : 29 - 66
  • [7] Prostate cancer incidence and mortality rates among white and black men
    Merrill, RM
    Brawley, OW
    [J]. EPIDEMIOLOGY, 1997, 8 (02) : 126 - 131
  • [8] Analysis of repeated biopsy results within 1 year after a noncancer diagnosis - Reply
    O'Dowd, GJ
    Miller, MC
    Orozco, R
    Veltri, RW
    [J]. UROLOGY, 2000, 55 (04) : 559 - 559
  • [9] Combination of prostate-specific antigen, clinical stage, and gleason score to predict pathological stage of localized prostate cancer - A multi-institutional update
    Partin, AW
    Kattan, MW
    Subong, ENP
    Walsh, PC
    Wojno, KJ
    Oesterling, JE
    Scardino, PT
    Pearson, JD
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (18): : 1445 - 1451
  • [10] Prostate specific antigen: A decade of discovery - What we have learned and where we are going
    Polascik, TJ
    Oesterling, JE
    Partin, AW
    [J]. JOURNAL OF UROLOGY, 1999, 162 (02) : 293 - 306